Publisher Reed Elsevier has announced the appointment of David Brennan as a member of the Supervisory Board of Reed Elsevier NV and as a non-executive director of Reed Elsevier PLC with effect from November 1, 2012, subject to shareholder approval at the respective Annual General Meetings to be held on April 24 and 25, 2012. He will also be appointed a non-executive director of Reed Elsevier Group plc.
Brennan is currently the Chief Executive Officer of AstraZeneca PLC, a global biopharmaceutical company, which develops, manufactures and markets prescription medicines. From 2001 until his appointment to CEO in 2006, Brennan was President and Chief Executive Officer of AstraZeneca's North American subsidiary. He was appointed an Executive Director of AstraZeneca PLC in 2005.
Reed Elsevier Group plc is a world leading provider of professional information solutions to the science and medical, legal, risk management, and business to business sectors. The group employs more than 30,000 people, including 16,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV.
To access our daily STM news feed through your iPhone, iPad, or other smartphones, please visit www.myscoope.com for a mobile friendly reading experience.
